re: SNDX p.s. The PFS data are due in 4Q18 (not 3Q18), as far as I know. -- PFS results from pivotal Phase 3 E2112 trial of entinostat plus exemestane in HR+, HER2- breast cancer expected in 3Q18 -- https://finance.yahoo.com/news/syndax-pharmaceuticals-reports-first-quarter-200500339.html Bladerunner